Erik Nordkamp, Managing Director of Pfizer UK explains why Pfizer has partnered with the Science Museum to sponsor its new exhibition on antibiotic resistance.
Antibiotics have revolutionised how we treat infectious diseases. Some of us will require an antibiotic at some point in our lives, and many medical interventions depend on them, but some bacteria are now becoming resistant to antibiotics.
The scale of the threat this poses to our health cannot be underestimated – it could threaten millions of lives worldwide by 2050.
Erik Nordkamp, Managing Director of Pfizer UK
Pfizer was among the first pharmaceutical companies to successfully mass produce penicillin in the 1950s, and were one of the leading companies and signatories of the Davos Declaration on Combating Antimicrobial Resistance in 2016, signed by more than 100 companies and 13 trade associations.
We currently provide health care providers and patients access to one of the most comprehensive portfolios of anti-infective medicines in the industry, and we've worked on the development of a number of education programmes and policies to address the ever evolving challenges in infectious disease.
However, no one person or organisation has all the answers, nor is there one solution to the challenge. Industry, governments, and health providers must work together and raise greater public awareness and understanding of how we can all help to win the fight against the superbugs.
To help raise the public's awareness of this critical issue, Pfizer has partnered with the Science Museum to sponsor its latest exhibition, called Superbugs: the Fight for Our Lives.
The exhibition runs until spring 2019. An estimated three million visitors will get to see real bacteria up close, including nine deadly superbugs that the World Health Organisation classifies as a significant threat to human health.
Visitors can also learn more about the people on the front line in the fight against superbugs, from a superbug survivor to healthcare professionals preventing infections, and a designer's solutions to stop bacteria spreading. Importantly, the exhibition highlights the role that we all have to play in this fight.
The stakes are high, but with the opening of this exhibition, Public Health England's new campaign to Keep Antibiotics Working, and renewed commitment from leaders at last month's conference in Berlin, it feels like we are finally gaining momentum in the fight against superbugs.
At Pfizer, we are ready and committed to playing our part in averting this growing crisis together.
 Dr Diane Ashiru-Oredope, (2015). Antibiotic Resistance: why the fuss and what simple actions can everyone take? Available at: https://longitudeprize.org/blog-post/antibiotic-resistance-why-fuss-and-what-simple-actions-can-everyone-take [Last accessed November 2017]
 Public Health England. Health matters: antimicrobial resistance. Published 10 December 2015. Available at: https://www.gov.uk/government/publications/health-matters-antimicrobial-resistance/health-matters-antimicrobial-resistance [Last accessed November 2017]
 Review on Antimicrobial Resistance. Antimicrobial Resistance: Tackling a crisis for the health and wealth of nations. Chaired by Jim O'Neill. December 2014.
 Pfizer. Our history. http://www.pfizer.co.uk/our-history [Last accessed January 2018]
 Pfizer policy position on antimicrobial resistance. September 2016. Available at: http://www.pfizer.com/files/news/PfizerPolicyPositionOnAntimicrobialResistance.pdf [Last accessed November 2017]
 Pfizer 2016 Annual Review. Available at: https://www.pfizer.com/files/investors/financial_reports/annual_reports/2016/our-business/global-businesses/pfizer-essential-health/index.html [Last accessed November 2017]